My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Ovid Therapeutics Inc. - Common Stock (NQ:OVID)

1.400 +0.180 (+14.75%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ovid Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023 ↗

June 14, 2023

Via Benzinga

Ovid Therapeutics Earnings Perspective: Return On Capital Employed ↗

May 22, 2023

Via Benzinga

Ovid Therapeutics: Q1 Earnings Insights ↗

May 05, 2023

Via Benzinga

Looking Into Ovid Therapeutics's Return On Capital Employed ↗

March 15, 2023

Via Benzinga

Ovid Therapeutics: Q1 Earnings Insights ↗

May 10, 2022

Ovid Therapeutics (NASDAQ:OVID) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

May 05, 2023

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

May 01, 2023

From Ovid Therapeutics Inc.

Via GlobeNewswire

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting

April 27, 2023

From Ovid Therapeutics Inc.

Via GlobeNewswire

The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech ↗

April 14, 2023

One executive called this the most "damaging" decision in five decades.

Via Investor's Business Daily

New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗

April 12, 2023

New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...

Via Benzinga

Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗

April 11, 2023

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...

Via Benzinga

Drugmakers Stand Up for Reproductive Rights: Pfizer and Biogen Among 300 Condemning Abortion Pill Approval Suspension ↗

April 11, 2023

Via Benzinga

Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

March 13, 2023

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

March 09, 2023

From Ovid Therapeutics Inc.

Via GlobeNewswire

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

March 08, 2023

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

February 28, 2023

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

February 08, 2023

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

January 05, 2023

A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

December 02, 2022

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights

November 08, 2022

From Ovid Therapeutics Inc.

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Thursday ↗

May 26, 2022

On Thursday, 94 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

May 23, 2022

On Monday, 149 companies reached new 52-week lows.

Via Benzinga

3 Biotech Stocks Under $10 to Add to Your Buy List ↗

April 26, 2022

These biotech stocks to buy are all profitable, which is important for investors looking to reduce their investment risk.

Via InvestorPlace

Overview Of Value Stocks In The Healthcare Sector ↗

April 11, 2022

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E...

Via Benzinga

Overview Of Value Stocks In The Healthcare Sector ↗

February 21, 2022

What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 27, 2022

Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) stock increased by 28.7% to $2.24 during Thursday's pre-market session. The company's market cap stands at $31.4...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

January 27, 2022

Good morning, trader! We're starting off the day with an overview of the biggest pre-market stock movers to watch on Thursday!

Via InvestorPlace

Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact ↗

January 03, 2022

Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small...

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

December 27, 2021

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.